Afatinib in EGFR TKI-Naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: a pooled analysis of three phase IIIb …
A Passaro, F de Marinis, HY Tu, KK Laktionov… - Frontiers in …, 2021 - frontiersin.org
Background Afatinib is approved for first-line treatment of patients with epidermal growth
factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC). Here, we …
factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC). Here, we …
[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - Elsevier
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer …
K Park, JS Kim, JH Kim, YC Kim, HG Kim, EK Cho… - BMC cancer, 2021 - Springer
Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in …
HY Tu, J Feng, M Shi, J Zhao, Y Wang, J Chang… - Targeted Oncology, 2022 - Springer
Background Afatinib has been shown as a suitable option for the treatment of epidermal
growth factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC) in …
growth factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC) in …
[HTML][HTML] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
SY Lee, CM Choi, YS Chang, KY Lee… - … lung cancer Research, 2021 - ncbi.nlm.nih.gov
Background We investigated the clinical characteristics and treatment outcomes of Korean
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
K Park, D Wan-Teck Lim, I Okamoto… - … advances in medical …, 2019 - journals.sagepub.com
Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - journals.sagepub.com
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
Introduction Previously, we developed a database of 693 patients with NSCLC and
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …